miR21抑制剂对肺腺癌细胞A-549的抑制效果  

Inhibition of miR21 inhibitor on A-549 cells in vitro

作　　者：姜学东[1] 王琼[1] 刘长浩[1] 王国柱[1] 

机构地区：[1]武警辽宁总队医院胸外科,沈阳110034

出　　处：《武警医学》2014年第5期500-502,506,共4页Medical Journal of the Chinese People's Armed Police Force

摘　　要：目的探讨miR21抑制剂转染人肺腺癌细胞A-549对其体外侵袭及血管形成能力的影响。方法 miR21抑制剂转染A-549细胞,同时设置未转染的A-549细胞作为对照组,转染24、48、72及96 h后,四甲基偶唑氮法(MTT)法检测两组细胞增殖抑制率;Transwell方法检测miR21抑制剂对A-549细胞侵袭的影响;小管形成实验检测miR21抑制剂对血管形成的影响。结果转染24 h,两组抑制率比较,差别无统计学意义;转染48 h及以后,抑制剂组抑制率均高于对照组,差别有统计学意义(P<0.05)。Transwell检测结果显示miR21抑制剂组每个视野细胞数(11.60±5.32)个远少于对照组(107.60±3.21)个,两组差别有统计学意义(P<0.01)。抑制剂组每视野小管计数平均(159.30±0.51)个,远少于对照组(508.80±1.30)个,两组差别有统计学意义(P<0.01)。结论 miR21抑制剂能够明显抑制A-549的侵袭能力,并能明显抑制血管内皮细胞血管生成,提示miR21抑制剂可以作为潜在的肺癌基因治疗的新方法。Objective To study the inhibition of miR21 inhibitor on the invasion and anti-angiogenesis of A-549 cells.Methods MiR21 inhibitor was transfected into A-549,and the control group was set up.24,48,72,96 hours after transfection,the effect of growth suppressing was quantified by 3-2 （4,5-dimethylthiazol-2-yl） 2,5-diphenyltetrazolium bromide （MTF） assay,anti-invasion was observed by transwell assay.Tube formation assay was used to detect the effects of miR21 inhibitor on human umbilical vein endothelial cells （HUVEC） angiogenesis.Results Twenty-four hours after transfection,the suppressing rate was different between the two groups;48,72,96 h after transfection,the suppressing rates in inhibition group were higher than those in control group,the difference was statistically significant （P 〈 0.05）.By transwell assay,number of cells in inhibition group （11.60 ± 5.32） was less than that in control group （107.60 ± 3.21）,the difference was statistically significant （P 〈 0.01）.Tubes in inhibition group （159.30 ± 0.51） was less than that in control group （508.80 ± 1.30）,the difference was statistically significant（P 〈0.01）.Conclusions miR21 inhibitor can inhibit the invasion of A-549 and angiogenesis of HUVEC.miR21 inhibitor can be a potential gene-therapy for gastric carcinoma.

关 键 词：miR21抑制剂 细胞侵袭 血管形成 肺腺癌 

分 类 号：R734.2[医药卫生—肿瘤]